Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CDK6 Antibodies:
anti-Mouse (Murine) CDK6 Antibodies:
anti-Rat (Rattus) CDK6 Antibodies:
Go to our pre-filtered search.
Human Polyclonal CDK6 Primary Antibody for IF (p), IHC (p) - ABIN670236
Yang, Wang, Hui, Li, Jiang: SOX 1, contrary to SOX 2, suppresses proliferation, migration, and invasion in human laryngeal squamous cell carcinoma by inhibiting the Wnt/?-catenin pathway. in Tumour biology 2015
Show all 4 Pubmed References
Human Monoclonal CDK6 Primary Antibody for ICC, WB - ABIN3043634
Ren, Huang, Xu, Yang, Yang, Hu: Isoflavone lupiwighteone induces cytotoxic, apoptotic, and antiangiogenic activities in DU-145 prostate cancer cells. in Anti-cancer drugs 2015
Show all 2 Pubmed References
Human Polyclonal CDK6 Primary Antibody for WB - ABIN3042894
Zhou, Lu, Liu, Guo, Liu, Zhou, Yang, Mi, Xu: Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo. in Current cancer drug targets 2015
Show all 2 Pubmed References
Human Monoclonal CDK6 Primary Antibody for IF, IHC (p) - ABIN560298
Quinn, Glassford, Percy, Munson, Marafioti, Rodriguez-Justo, Yong: APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. in Blood 2011
Show all 2 Pubmed References
Human Polyclonal CDK6 Primary Antibody for IF, IHC - ABIN349201
Tur, Etschmann, Benz, Leich, Waller, Schuh, Rosenwald, Ertl, Kienitz, Haaf, Bräuninger, Gattenlöhner: The 140-kD isoform of CD56 (NCAM1) directs the molecular pathogenesis of ischemic cardiomyopathy. in The American journal of pathology 2013
metabolic function of cyclin D3 (show CCND3 Antibodies)-CDK6 kinase in cancer cell survival
Describe a regulatory loop miR (show MLXIP Antibodies)-218-CDK6/CyclinD1-E2F1 (show E2F1 Antibodies) whose disruption may contribute to cell cycle progression in gastric cancer.
Specific E2Fs also have prognostic value in breast cancer, independent of clinical parameters. We discuss here recent advances in understanding of the RB-E2F (show E2F1 Antibodies) pathway in breast cancer. We also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 (show CDK4 Antibodies) inhibitors in breast cancer for the development of more effective combination therapies.
The deletion of CBX3 (show CBX3 Antibodies) directly enforces the expression of CDK6 and p21 (show CDKN1A Antibodies).
Amplification of the G1-S regulatory genes, CCNE1, CCND1 and CdK6, represent an early event, which precedes ERBB2, EGFR, or KRAS amplification in gastric adenocarcinoma.
CDK6-mediated suppression of CD25 (show IL2RA Antibodies) is required for initiation of T-ALL by activated Notch1 (show NOTCH1 Antibodies)
CDK6 overexpression is associated with cancer.
High CDK6 expression is associated with Melanoma.
Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
Our study proved that the CDK6 gene is a target of miR (show MLXIP Antibodies)-637, and demonstrated the regulatory association between miR (show MLXIP Antibodies)-637 and CDK6
PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6 (show CDK4 Antibodies)), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 (show CDK4 Antibodies) inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration.
CDK6-mediated suppression of CD25 (show IL2RA Antibodies) is required for initiation of T-ALL by activated Notch1 (show NOTCH1 Antibodies). . Pharmacologic inhibition of CDK6 kinase induces CD25 (show IL2RA Antibodies) and RUNX1 (show RUNX1 Antibodies) expression, cell cycle arrest and apoptosis in mouse and human T-ALL.
Fbxo7 (show FBXO7 Antibodies)-deficient immature thymocytes failed to undergo expansion in the thymus due to a lack of Cdk6 activity, while mature T cells showed enhanced proliferative capacity upon T-cell receptor engagement due to reduced p27 (show CDKN1B Antibodies) levels. These studies reveal differential cell cycle regulation by Fbxo7 (show FBXO7 Antibodies) at different stages in T-cell development.
Taken together, our results suggested that microRNA-33 enhanced the replicative senescence of MEFs potentially by suppressing CDK6 expression.
Data show that E11/glycoprotein 38 (show PDPN Antibodies)(GP38 (show PDPN Antibodies)) was up-regulated upon SEMA3A (show SEMA3A Antibodies) stimulation, and cyclin-dependent kinase 6 (CDK6) was down-regulated in a time-dependent manner.
Notch3 (show NOTCH3 Antibodies) transcription and growth of lymphoma cells was dependent on CDK6.
CDK6 is an important regulator of stem cell activation and an essential component of a transcriptional complex that suppresses Egr1 (show EGR1 Antibodies) in hematopoietic and leukemic stem cell activation
Cdk4 (show CDK4 Antibodies) and Cdk6 cooperate in hematopoietic tumor development and suggest a role for Cdk6 in sequestering INK4 (show CDKN2A Antibodies) proteins away from Cdk4 (show CDK4 Antibodies).
Cdk6/Ccnd1 (show CCND1 Antibodies) overexpression inhibits chondrocyte maturation and enhances G1/S transition by phosphorylating pRb (show PGR Antibodies); the chondrocytes then undergo p53 (show TP53 Antibodies)-dependent apoptosis
p107 (show RBL1 Antibodies) retinoblastoma protein is regulated by Cdk6/Ccnd1 (show CCND1 Antibodies) in growth plates.
the T-1075C SNP of bovine CDK6 is significantly associated with body length and heart girth
The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. Expression of this gene is up-regulated in some types of cancer. Multiple alternatively spliced variants, encoding the same protein, have been identified.
cyclin-dependent kinase 6
, cell division protein kinase 6-like
, cell division protein kinase 6
, serine/threonine-protein kinase PLSTIRE
, CR2 protein kinase